Episode 39: From Harvard to Hollywood
Emmy-nominated alum combines medicine, media and storytelling (Source: Harvard Medical Labcast)
Source: Harvard Medical Labcast - January 24, 2018 Category: Biomedical Science Authors: Harvard Medical School Office of Communications and External Relations Source Type: podcasts
Engaging Patient in End of Life Care Data Suggest Less Cost
Jennifer S. Temel, MD of Mass General Hospital - Harvard Medical School discusses how engaging patient in end of life care and that the data suggest it will ultimately cost less. From the 22nd Annual ...
Author: thoraciconcology
Added: 01/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Involving Palliative Specialist Earlier Patient Twice as Likely to Discuss End Of Life
Jennifer S. Temel, MD of Mass General Hospital - Harvard Medical School discusses how involving palliative specialist earlier in the process makes patient twice as likely to discuss end of life. From ...
Author: thoraciconcology
Added: 01/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Most Patients Prefer to Die At Home Honest and Open Communication is Key
Jennifer S. Temel, MD of Mass General Hospital - Harvard Medical School discusses how most patients prefer to die at home and that an honest and open communication is key. From the 22nd Annual Perspec...
Author: thoraciconcology
Added: 01/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Patient Prognosis Perception Impacts Medical Care and Quality of Life
Jennifer S. Temel, MD of Mass General Hospital - Harvard Medical School discusses patient prognosis perception and how it impacts medical care and quality of life. From the 22nd Annual Perspectives in...
Author: thoraciconcology
Added: 01/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Prognosis, Treatment Goals & End of Life Should Not Be Viewed as One Time Conversations
Jennifer S. Temel, MD of Mass General Hospital - Harvard Medical School discusses how prognosis, treatment goals and how end of life care should not be viewed as one time conversations. From the 22nd ...
Author: thoraciconcology
Added: 01/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 4, 2018 Category: Cancer & Oncology Source Type: podcasts
3-dimensional (3D) Organoids for Renal Cell Carcinoma Research
Leigh Ellis Ph.D. Assistant Professor Department of Oncologic Pathology Dana-Farber Cancer Institute Brigham and Womens Hospital Harvard Medical School discusses 3-dimensional (3D) Organoids for Rena...
Author: kidneycancer
Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts
Promising News in Melanoma From Annual Meeting 2017
As part of our coverage from the 2017 American Society of Clinical Oncology annual meeting, Dr. Ryan Sullivan from Massachusetts General Hospital Cancer Center and Harvard Medical School provides a po...
Author: patientpower
Added: 06/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2017 Category: Cancer & Oncology Source Type: podcasts
Promising News in Melanoma From ASCO 2017
As part of our coverage from the 2017 American Society of Clinical Oncology annual meeting, Dr. Ryan Sullivan from Massachusetts General Hospital Cancer Center and Harvard Medical School provides a po...
Author: patientpower
Added: 06/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2017 Category: Cancer & Oncology Source Type: podcasts
Have you adopted vemurafenib in BRAF+ mutated metastatic CRC?
Jeffrey Meyehardt, MD of Harvard Medical School discusses the use of vemurafenib in BRAF+ mutated metastatic colorectal cancer at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Is SIRT effective in the treatment of metastatic HCC?
Jeffrey Meyehardt, MD of Harvard Medical School explains whether or not selective internal radiation therapy (SIRT) is effective in treating metastatic hepatocellular carcinoma (HCC) at the 2017 ASCO ...
Author: obr
Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts
What is the optimal duration of therapy in stage III colon cancer patients?
Jeffrey Meyehardt, MD of Harvard Medical School discusses the optimal duration of therapy for patients with stage III colon cancer at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts
How are immunotherapies being studied in gastric and esophageal cancers?
Jeffrey Meyehardt, MD of Harvard Medical School discusses how immunotherapy is being studied and implemented in the treatment of gastric and esophageal cancers at the 2017 ASCO Annual Meeting in Chica...
Author: obr
Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Treatment Trends 2017 for Breast Cancer
Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center gives an overview of the treatment trends for 2017 in breast cancer treatment. He discusses two promis...
Author: ASCO2017
Added: 06/12/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 12, 2017 Category: Cancer & Oncology Source Type: podcasts
Whats Next for RAD1901?
Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses the next step for RAD1901 and his plans for the next trial at the 2017 ASCO Annual Meeting i...
Author: ASCO2017
Added: 06/12/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 12, 2017 Category: Cancer & Oncology Source Type: podcasts
